Neurofibromatosis Type 2
Showing 1 - 25 of >10,000
Natural History Study of Patients With Neurofibromatosis Type 2
Recruiting
- Neurofibromatosis
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jan 25, 2023
89Zr-Bevacizumab PET/CT Imaging in NF2 Patients
Recruiting
- Neurofibromatosis 2
- Bevacizumab Zirconium Zr-89
-
Leiden, Zuid-Holland, NetherlandsLeiden University Medical Center
Jan 5, 2023
Neurofibromatosis Type 2, Vestibular Schwannomas Trial in New York (Axitinib)
Completed
- Neurofibromatosis Type 2
- Vestibular Schwannomas
-
New York, New YorkNYU Langone Medical Center
Nov 24, 2021
Neurofibromatosis Type 2, Neuroma, Acoustic Trial in Los Angeles (RAD001, everolimus)
Active, not recruiting
- Neurofibromatosis Type 2
- Neuroma, Acoustic
- RAD001, everolimus
-
Los Angeles, CaliforniaUniversity of California Los Angeles
Mar 2, 2022
Neurofibromatosis 2, Progressive Vestibular Schwannoma (VS) Trial in United States (Crizotinib)
Active, not recruiting
- Neurofibromatosis 2
- Progressive Vestibular Schwannoma (VS)
-
Birmingham, Alabama
- +16 more
Jan 3, 2023
Vestibular Schwannoma, Neurofibromatosis Type 2 Trial in Beijing (Icotinib)
Completed
- Vestibular Schwannoma
- Neurofibromatosis Type 2
-
Beijing, Beijing, China
- +1 more
Sep 8, 2021
Disfigurement From Photographs of Neurofibromatosis Type 1
Completed
- Neurofibromatosis 1
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jan 20, 2023
Neurofibromatosis 1 (NF1), Plexiform Neurofibromas (PN) Trial run by the NCI (Selumetinib)
Active, not recruiting
- Neurofibromatosis 1 (NF1)
- Plexiform Neurofibromas (PN)
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jan 31, 2023
Hypertension, Neurofibromatosis 1, Blood Pressure Trial in Parkville (Group 1. Standard Home Blood Pressure Measurement, Group
Not yet recruiting
- Hypertension
- +2 more
- Group 1. Standard Home Blood Pressure Measurement
- Group 2. Hypnosis script prior to home blood pressure measurement
-
Parkville, Victoria, AustraliaMurdoch Children's Research Institute
Feb 8, 2022
Mitochondrial Dysfunction in Neurofibromatosis Type 1
Not yet recruiting
- Neurofibromatosis 1
- Blood draw
- FACIT-F and Pain Scales
- (no location specified)
Jun 12, 2023
Familial Investigations of Childhood Cancer Predisposition
Recruiting
- Acute Leukemia
- +45 more
-
Memphis, TennesseeSt. Jude Children's Research Hospital
May 11, 2022
Neurofibromatosis 1 Trial in Boston (Deoxycholic Acid, Polidocanol, 1064nm Nd:YAG laser)
Not yet recruiting
- Neurofibromatosis 1
- Deoxycholic Acid
- +3 more
-
Boston, MassachusettsWellman Center for Photomedicine
Nov 13, 2023
Neurofibromatosis 1, Plexiform Neurofibroma, NF1 Trial (Test group (Group A): FCN-159 8 mg, orally, once daily;, Control group
Not yet recruiting
- Neurofibromatosis 1
- +2 more
- Test group (Group A): FCN-159 8 mg, orally, once daily;
- Control group (Group B): Placebo, orally, once daily;
- (no location specified)
Jun 16, 2023
Biology of Skin Neurofibromas in Neurofibromatosis Type 1
Completed
- Neurofibromatosis Type 1
- Neurofibroma
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jan 20, 2023
Neurofibromatosis 1 and 2 (NF1 and NF2) Trial in New York (hand-held dynamometer)
Completed
- Neurofibromatosis 1 and 2 (NF1 and NF2)
- hand-held dynamometer
-
New York, New YorkNew York School of Medicine
Mar 16, 2021
US Selumetinib Registry
Not yet recruiting
- Neurofibromatosis Type 1
- Plexiform Neurofibromas
- (no location specified)
Jan 5, 2023
Neurofibromatosis 1, Neurofibroma Plexiform Trial in Shanghai (Selumetinib)
Active, not recruiting
- Neurofibromatosis 1
- Neurofibroma Plexiform
-
Shanghai, China
- +1 more
Jan 13, 2023
Neurofibromatosis 1 Trial run by the National Cancer Institute (NCI) (Abemaciclib)
Recruiting
- Neurofibromatosis 1
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jan 20, 2023
Neurofibromatosis Type 2, Progressive Vestibular Schwannomas Trial in United States (Bevacizumab)
Completed
- Neurofibromatosis Type 2
- Progressive Vestibular Schwannomas
-
Los Angeles, California
- +11 more
Jan 26, 2021
Plexiform Neurofibroma, Neurofibromatosis Type 1 (NF1) Trial in United States (Mirdametinib (PD-0325901) oral capsule or
Active, not recruiting
- Plexiform Neurofibroma
- Neurofibromatosis Type 1 (NF1)
- Mirdametinib (PD-0325901) oral capsule or dispersible tablet
-
Birmingham, Alabama
- +49 more
Nov 17, 2022
Development to Predict Malignant Conversion in Neurofibromatosis
Recruiting
- Neurofibromatosis 1
- +2 more
- Whole Body Magnetic Resonance Imaging
-
Baltimore, MarylandJohns Hopkins University
Dec 22, 2022
Cutaneous Neurofibroma Trial in Boston (Kybella, 980nm laser, 755nm Alexandrite Laser)
Recruiting
- Cutaneous Neurofibroma
- Kybella
- +3 more
-
Boston, MassachusettsWellman Center for Photomedicine, Massachusetts General Hospital
Aug 10, 2022
Stressors in Parents of Cancer or Neurofibromatosis Type 1 (NF1)
Completed
- Parents of Children With Cancer
- +2 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jan 26, 2023